Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration
DRKS00007777Phase 4Recruiting
- Sponsor
- Universitätsklinikum Münster
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alemtuzumab in multiple sclerosis (MS), sponsored by Universitätsklinikum Münster. Started Mar 2015; status: recruiting.
02
Drugs
alemtuzumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on DRKS00007777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00007777.